Abstract
Currently recommended management of acute gastroenteritis is supportive. Although the affected children habitually have vomiting, recommendations do not focus on the correction of this symptom. In this condition, elevated ketone bodies and stimuli initiated by gut mucosa damage produced by the enteral pathogen likely underlay nausea and vomiting. As compared to 0.9% saline, intravenous administration of a dextrose-containing bolus of 0.9% saline is associated with a greater reduction of circulating ketones and a shorter duration of nausea and vomiting. Nonetheless, this treatment strategy is not followed by a lower rate of hospitalization. Conclusion: Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration.(Table presented.)
| Original language | English |
|---|---|
| Pages (from-to) | 1-5 |
| Number of pages | 5 |
| Journal | European Journal of Pediatrics |
| Volume | 177 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Keywords
- Acute gastroenteritis
- Antagonists of the type 3 serotonin receptor
- Ketosis
- Ondansetron
- Vomiting
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Clinical Practice : Nausea and vomiting in acute gastroenteritis: physiopathology and management. / Canziani, Beatrice C.; Uestuener, Peter; Fossali, Emilio F.; Lava, Sebastiano A.G.; Bianchetti, Mario G.; Agostoni, Carlo; Milani, Gregorio P.
In: European Journal of Pediatrics, Vol. 177, No. 1, 2018, p. 1-5.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical Practice
T2 - Nausea and vomiting in acute gastroenteritis: physiopathology and management
AU - Canziani, Beatrice C.
AU - Uestuener, Peter
AU - Fossali, Emilio F.
AU - Lava, Sebastiano A.G.
AU - Bianchetti, Mario G.
AU - Agostoni, Carlo
AU - Milani, Gregorio P.
PY - 2018
Y1 - 2018
N2 - Currently recommended management of acute gastroenteritis is supportive. Although the affected children habitually have vomiting, recommendations do not focus on the correction of this symptom. In this condition, elevated ketone bodies and stimuli initiated by gut mucosa damage produced by the enteral pathogen likely underlay nausea and vomiting. As compared to 0.9% saline, intravenous administration of a dextrose-containing bolus of 0.9% saline is associated with a greater reduction of circulating ketones and a shorter duration of nausea and vomiting. Nonetheless, this treatment strategy is not followed by a lower rate of hospitalization. Conclusion: Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration.(Table presented.)
AB - Currently recommended management of acute gastroenteritis is supportive. Although the affected children habitually have vomiting, recommendations do not focus on the correction of this symptom. In this condition, elevated ketone bodies and stimuli initiated by gut mucosa damage produced by the enteral pathogen likely underlay nausea and vomiting. As compared to 0.9% saline, intravenous administration of a dextrose-containing bolus of 0.9% saline is associated with a greater reduction of circulating ketones and a shorter duration of nausea and vomiting. Nonetheless, this treatment strategy is not followed by a lower rate of hospitalization. Conclusion: Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration.(Table presented.)
KW - Acute gastroenteritis
KW - Antagonists of the type 3 serotonin receptor
KW - Ketosis
KW - Ondansetron
KW - Vomiting
UR - http://www.scopus.com/inward/record.url?scp=85030181826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030181826&partnerID=8YFLogxK
U2 - 10.1007/s00431-017-3006-9
DO - 10.1007/s00431-017-3006-9
M3 - Article
VL - 177
SP - 1
EP - 5
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 1
ER -